NO20020639L - Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg - Google Patents

Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg

Info

Publication number
NO20020639L
NO20020639L NO20020639A NO20020639A NO20020639L NO 20020639 L NO20020639 L NO 20020639L NO 20020639 A NO20020639 A NO 20020639A NO 20020639 A NO20020639 A NO 20020639A NO 20020639 L NO20020639 L NO 20020639L
Authority
NO
Norway
Prior art keywords
antibody
treatment
bone marrow
hodgkins lymphoma
involving bone
Prior art date
Application number
NO20020639A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020639D0 (no
Inventor
William Rastetter
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20020639D0 publication Critical patent/NO20020639D0/no
Publication of NO20020639L publication Critical patent/NO20020639L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20020639A 1999-08-11 2002-02-08 Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg NO20020639L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
PCT/US2000/040459 WO2001010462A1 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Publications (2)

Publication Number Publication Date
NO20020639D0 NO20020639D0 (no) 2002-02-08
NO20020639L true NO20020639L (no) 2002-04-11

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020639A NO20020639L (no) 1999-08-11 2002-02-08 Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg

Country Status (10)

Country Link
EP (1) EP1207906A4 (enExample)
JP (1) JP2003513012A (enExample)
CN (2) CN100389825C (enExample)
AU (1) AU784971B2 (enExample)
CA (1) CA2378646A1 (enExample)
MX (1) MXPA02001398A (enExample)
MY (1) MY136635A (enExample)
NO (1) NO20020639L (enExample)
TW (1) TWI279233B (enExample)
WO (1) WO2001010462A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
PT1631313E (pt) 2003-06-05 2015-07-02 Genentech Inc Terapêutica de combinação para distúrbios de células b
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
PL4365189T3 (pl) 2007-07-09 2025-05-26 F. Hoffmann-La Roche Ag Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP5738196B2 (ja) * 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
EP3247395A1 (en) * 2015-01-23 2017-11-29 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114057885A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
US20190192703A1 (en) * 2016-09-16 2019-06-27 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
KR101063278B1 (ko) * 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy

Also Published As

Publication number Publication date
MXPA02001398A (es) 2002-08-12
HK1048945A1 (zh) 2003-04-25
AU784971B2 (en) 2006-08-10
NO20020639D0 (no) 2002-02-08
MY136635A (en) 2008-11-28
CN101259270A (zh) 2008-09-10
TWI279233B (en) 2007-04-21
AU7626000A (en) 2001-03-05
WO2001010462A1 (en) 2001-02-15
CN1373671A (zh) 2002-10-09
EP1207906A1 (en) 2002-05-29
CA2378646A1 (en) 2001-02-15
CN100389825C (zh) 2008-05-28
EP1207906A4 (en) 2005-07-06
JP2003513012A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
NO20020639L (no) Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20016035D0 (no) Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
PL356180A1 (en) Hair treatment compositions comprising particulate substances
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
IL149896A0 (en) Substituted oxazolidinones and their use in the field of blood coagulation
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
PL356784A1 (pl) Substancja do zastosowania w leczeniu łuszczycy
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
PT1152756E (pt) Derivados de anticonvulsivo uteis no tratamento do autismo
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
DE10081194D2 (de) Darreichungsform zur Applikation in Körperöffnungen
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
AU5565401A (en) Materials and methods for the treatment of depression
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EE200200348A (et) Ravimkoostis kasutamiseks valu ravis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application